Navidea Biopharmaceuticals, Inc. NAVBQ
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 600.00 | 7.50K | 57.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 600.00 | 7.50K | 57.50K |
| Cost of Revenue | -- | -- | 50.00K | 134.40K | 500.00 |
| Gross Profit | -- | -- | -49.40K | -126.90K | 57.10K |
| SG&A Expenses | 1.32M | 1.15M | 1.30M | 1.04M | 1.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.43M | 2.42M | 3.24M | 2.36M | 2.98M |
| Operating Income | -2.43M | -2.42M | -3.24M | -2.35M | -2.92M |
| Income Before Tax | -1.39M | -1.48M | -3.48M | -5.71M | -3.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.39M | -1.48M | -3.48M | -5.71M | -3.00M |
| Earnings from Discontinued Operations | 7.43M | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 0.00 | 0.00 | -- | 0.00 |
| Net Income | 6.03M | -1.48M | -3.48M | -5.71M | -3.00M |
| EBIT | -2.43M | -2.42M | -3.24M | -2.35M | -2.92M |
| EBITDA | -2.40M | -2.39M | -3.22M | -2.33M | -2.90M |
| EPS Basic | 0.12 | -0.05 | -0.11 | -0.25 | -0.10 |
| Normalized Basic EPS | -0.04 | -0.03 | -0.05 | -0.05 | -0.06 |
| EPS Diluted | 0.12 | -0.05 | -0.11 | -0.25 | -0.10 |
| Normalized Diluted EPS | -0.04 | -0.03 | -0.05 | -0.05 | -0.06 |
| Average Basic Shares Outstanding | 48.24M | 32.65M | 32.38M | 30.73M | 30.27M |
| Average Diluted Shares Outstanding | 48.24M | 32.65M | 32.38M | 30.73M | 30.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |